You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: 100

    PROJECT SUMMARY Optic neuritis (ON) is an acute autoimmune disease caused by immune attack on the myelin that protects the optic nerve leading to vision loss. Steroid treatments accelerate recovery of visual acuity in some patients but have no effect on other visual functions such as contrast sensitivity that are important for activities of daily life. Even with steroid treatments, 13,000 ON patie ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin

    SBC: NEUIMMUNE BIOLOGICS, INC.            Topic: NHLBI

    ABSTRACTAlpha-1 antitrypsin (A1AT) is well-established as a biotherapeutic used for the treatment of alpha-1 antitrypsin deficiency, and shows promise for treating a variety of other diseases. However, A1AT augmentation therapy carries unnecessary risk since it relies upon the weekly transfusion of plasma-derived product, which presents supply chain and contaminant risks. This could be remedied wi ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery

    SBC: BIOGRAFT, INC.            Topic: NHLBI

    Saphenous vein graft (SVG) failure following coronary artery bypass grafting (CABG) is a critical clinical problem, with recent studies revealing that as many as 25% of vein grafts develop stenosis within 12-18 months after surgery, and up to 50% of grafts occlude within 5-10 years. CABG surgery is the gold standard treatment for patients with severe multi-vessel disease, with over 370,000 procedu ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment

    SBC: ZYMO RESEARCH CORP.            Topic: NINDS

    PROJECT SUMMARY/ABSTRACT Stroke injury occurs over a long duration through pathologic changes leading to long-term neurologic dysfunction. There is an urgent need of therapeutic strategies that can provide safe and efficacious therapeutic effects to the hypoperfused brain with long-lasting endogenous neuroprotection for prevention of long-term neurologic dysfunction. Sufficient evidence has pointe ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. HBI-002 to Treat Parkinson’s Disease

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: 107

    PROJECT SUMMARY The goal of the proposed project is to evaluate the potential of HBI-002, a novel oral formulation of carbon monoxide (CO), as a neuroprotective agent in Parkinson’s disease (PD). A growing body of research suggests that low doses of CO - and the heme oxygenase (HO) enzymes that generate endogenous CO - protect against neuronal cell loss in PD, and epidemiologic studies have asso ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. A novel approach to restricting the spread of neurofibrillary tau

    SBC: NOVORON BIOSCIENCE INC            Topic: NIA

    7. Project Summary Alzheimer’s disease (AD) is the most common cause of dementia and is a growing problem as populations age. More than 25 million people are affected by dementia worldwide with most suffering from AD. AD is characterized by the presence of plaques of insoluble amyloid-beta (Aβ) and tangles of hyperphosphorylated aggregates of the cytoskeletal protein, tau. Thus far, most AD tre ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Bronchoscopic lung navigation system for accurately excising lung nodules

    SBC: Navigation Sciences, Inc.            Topic: 102

    ABSTRACT The long-term goal of this project is to develop and commercialize a navigation system that can accurately determine margins in real-time during surgery for lung cancer. Surgery is currently the standard of care for early stage lung cancer. A critical challenge is to reliably identify small, early-stage tumors and resect them with sufficient margins (distance between the edge of tumor and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy

    SBC: MICROCURES INC            Topic: 300

    Radical prostatectomy (RP) is a commonly used treatment option for localized prostate cancer, which carries a high risk for development of erectile dysfunction (ED) because of cavernous nerve (CN) injury. Even newer, nerve-sparing, robotic procedures do not convincingly improve erectile function (EF) outcomes after RP. In addition, ED resulting from RP is often refractory to treatment by orally ad ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. 'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics

    SBC: BUTO CORPORATION            Topic: NIA

    Abstract. Alzheimer’s disease (AD) affects more than 5M Americans today, and is the most common cause of dementia in adults. While current medications slightly delay symptoms, no medications exist to cure or stop disease progression. A current focus at NIA is to identify novel drug targets, that address resilience to AD; also, there is an increasing perspective at NIA that Multi-target therapy m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. A rapid test for congenital syphilis screening

    SBC: MelioLabs Inc.            Topic: NICHD

    PROJECT SUMMARY Since 2014, Congenital Syphilis (CS) cases in the United States, caused by the transplacental transmission of the bacterium Treponema pallidum from mother to child, have increased at an alarming rate. Targeted surveillance studies indicate a rise andgt;185% from 2014 to 2018 alone. Women who acquire syphilis within 4 years of pregnancy will transmit the infection to 80% of their fe ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government